The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Th17 Cells Explained

Th17 Cells Explained

February 1, 2008 • By Virginia Hughes

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BOSTON—In the early 1990s, immunologists thought there were just two types of helper T cells—Th1 and Th2—which, while not by themselves damaging, could activate other effector cells to promote disease. However, discoveries in last few years have proven that the T-cell world is actually much more diverse.

You Might Also Like
  • Salt as a Promoter of Th17 Cells and Autoimmune Disease
  • Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
Explore This Issue
February 2008
Also By This Author
  • Science from our Sisters

By 2000, researchers had discovered a third class of helper T cells that called into question everything known about Th1 and Th2. Surprisingly, these new cells—named Th17 because they secrete a cytokine called interleukin 17 (IL-17)—have some cytotoxic properties. Most interesting for rheumatologists, Th17 cells can display specificity for self-antigens, making them a crucial component of the development of inflammation and severe autoimmunity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Research Background

The history, developmental properties, and potential therapeutic targets of Th17 cells were discussed by Daniel Cua, PhD, a researcher at Schering-Plough Biopharma/DNAX in Palo Alto, Calif., at the ACR/ARHP Annual Scientific Meeting in Boston last November. He also presented new data, published in the December issue of Nature Immunology (2007;8:1390-1397), showing how specific cellular environments can lead to the pathogenic properties of Th17 cells.

“There’s so much work on Th17 cells coming out now, and so fast,” Dr. Cua said. “It’s really changing the way immunologists think about inflammatory diseases.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There’s so much work on Th17 cells coming out now, and so fast. It’s really changing the way immunologists think about inflammatory diseases.

—Daniel Cua, PhD

Practicing rheumatologists should pay attention to the new developments, he added, because the research will likely lead to effective therapies for autoimmune diseases. “There are no promises,” he cautioned, “but if you understand the disease process, then it makes sense that you can better treat it.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Cua’s research track started seven years ago when one of his colleagues at DNAX, Robert A. Kastelein, PhD, discovered another cytokine, interleukin 23 (IL-23). In pivotal genetic experiments, they found that animals lacking IL-23 were completely resistant to collagen-induced arthritis. In other words, as the DNAX team published in Nature (2003;421:744-748), IL-23 was required for joint inflammation.

The next step was figuring out how IL-23 worked at the cellular level. Claire Langrish, PhD, then a post-doc in Dr. Cua’s lab, first investigated the nature of the cytokines the IL-23 cells were producing. “She uncovered that what was missing in the IL-23–resistant animal was in fact IL-17,” Dr. Cua explained. IL-23 is required for the production of the cytokine interleukin 17, and it’s IL-17 that’s driving the resistance to inflammation.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Clinical research, inflammation, Pathogenesis, severe autoimmunity, Stem Cells, T-cellsIssue: February 2008

You Might Also Like:
  • Salt as a Promoter of Th17 Cells and Autoimmune Disease
  • Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
  • Th17 May Contribute to Bone Destruction by Modifying Osteoclasts

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.